---
stable_id: R-HSA-9691421
display_name: BTK binds BTK inhibitors
species: Homo sapiens
summary: Tyrosine-protein kinase BTK (aka Bruton Tyrosine Kinase) is essential for
  B-cell development and differentiation, and in B-cell receptor signalling. It plays
  an important role in the function of immune cells of innate and adaptive immunity.
  BTK inhibitors prevent the proliferation, trafficking, chemotaxis and adhesion of
  B cells. BTK is also a driving force for chronic lymphocytic leukemia (CLL) and
  other B cell malignancies.<br><br>Ibrutinib is a first-in-class BTK inhibitor that
  irreversibly binds to Cys-481 in BTK's kinase domain and potently blocks its enzymatic
  activity (Ponader et al. 2012). It is used to treat CLL and mantle cell lymphoma
  (MCL).<br><br>Acalabrutinib, a second-generation BTK inhibitor, is used for the
  treatment of CCL (Byrd et al. 2015) and MCL (Cheah et al. 2016). It is in clinical
  trial in COVID-19 patients as part of the UK's ACCORD initiative. Preliminary data
  from off-label use in the US suggests that acalabrutinib therapy normalises inflammatory
  markers such as CRP and IL6 in patients with severe COVID-19. Targeting host hyperinflammation
  via BTK inhibition may be a rational therapeutic strategy that may improve patient
  outcomes in this disease (Roschewski et al. 2020).<br><br>Other BTK inhibitors which
  target BTK include spebrutinib, tirabrutinib, naquotinib and zanubrutinib (Tanaka
  et al. 2020).
---

# BTK binds BTK inhibitors
**Reactome ID:** [R-HSA-9691421](https://reactome.org/content/detail/R-HSA-9691421)
**Species:** Homo sapiens

## Summary

Tyrosine-protein kinase BTK (aka Bruton Tyrosine Kinase) is essential for B-cell development and differentiation, and in B-cell receptor signalling. It plays an important role in the function of immune cells of innate and adaptive immunity. BTK inhibitors prevent the proliferation, trafficking, chemotaxis and adhesion of B cells. BTK is also a driving force for chronic lymphocytic leukemia (CLL) and other B cell malignancies.<br><br>Ibrutinib is a first-in-class BTK inhibitor that irreversibly binds to Cys-481 in BTK's kinase domain and potently blocks its enzymatic activity (Ponader et al. 2012). It is used to treat CLL and mantle cell lymphoma (MCL).<br><br>Acalabrutinib, a second-generation BTK inhibitor, is used for the treatment of CCL (Byrd et al. 2015) and MCL (Cheah et al. 2016). It is in clinical trial in COVID-19 patients as part of the UK's ACCORD initiative. Preliminary data from off-label use in the US suggests that acalabrutinib therapy normalises inflammatory markers such as CRP and IL6 in patients with severe COVID-19. Targeting host hyperinflammation via BTK inhibition may be a rational therapeutic strategy that may improve patient outcomes in this disease (Roschewski et al. 2020).<br><br>Other BTK inhibitors which target BTK include spebrutinib, tirabrutinib, naquotinib and zanubrutinib (Tanaka et al. 2020).
